Federated Hermes’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Federated Hermes’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-122	Closed	-$1K	–	2339
2022 Q1	$1K	Sell	122 -1,795	-94%	-$3.26K	﹤0.01%	2156
2021 Q4	$4K	Buy	+1,917	New	+$4.59K	﹤0.01%	2021
2019 Q4	–	Sell	-483	Closed	-$2K	–	2338
2019 Q3	$2K	Sell	483 -1,094	-69%	-$3.95K	﹤0.01%	2053
2019 Q2	$6K	Hold	1,577	–	–	﹤0.01%	1968
2019 Q1	$7K	Hold	1,577	–	–	﹤0.01%	1931
2018 Q4	$4K	Buy	+1,577	New	+$9.24K	﹤0.01%	2022
2018 Q1	–	Sell	-1,080	Closed	-$4K	–	2255
2017 Q4	$4K	Hold	1,080	–	–	﹤0.01%	2028
2017 Q3	$4K	Buy	1,080 +697	+182%	+$3.2K	﹤0.01%	2008
2017 Q2	$2K	Buy	+383	New	+$2.15K	﹤0.01%	2056
2016 Q3	–	Sell	-4,257	Closed	-$60K	–	2184
2016 Q2	$60K	Buy	+4,257	New	+$66.4K	﹤0.01%	1622
2014 Q4	–	Sell	-61	Closed	-$1K	–	2070
2014 Q3	$1K	Buy	+61	New	+$1.1K	﹤0.01%	1961

Other funds holding AGTC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes's AGTC Position: Q2 2022 in Review

Federated Hermes sold out of Applied Genetic Technologies Corporation (AGTC) in Q2 2022, closing a stake of 122 shares — an estimated $1K sold.

Federated Hermes first reported a position in AGTC in Q3 2014 and held it in 11 quarters. The position peaked at $60K in Q2 2016. 47 funds tracked by Wall St. Rank hold AGTC as of Q2 2022.

Federated Hermes reported no remaining Applied Genetic Technologies Corporation position as of Q2 2022 after selling out during the quarter.
Federated Hermes sold 122 Applied Genetic Technologies Corporation shares in Q2 2022, an estimated $1K.
Federated Hermes first reported a position in Applied Genetic Technologies Corporation in Q3 2014 and held it in 11 quarters.
Federated Hermes's Applied Genetic Technologies Corporation position peaked at $60K in Q2 2016.
47 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.